The association between the TLR2 signaling pathway and colon cancer development is further supported by the presence of genomic amplifications of the TLR2 downstream effectors IL-1 receptor-associated kinase (IRAK)1 and IRAK4 in 18% and 39.7% of colon cancer patients, respectively. The gene discussed is IRAK4; the disease is colonic neoplasm.